In a Phase 1a escalating clinical trial, autologous mesenchymal stem cell infusion for renovascular disease increases blood flow and the glomerular filtration rate while reducing inflammatory biomarkers and blood pressure-Reference-Cited by-同舟云学术

In a Phase 1a escalating clinical trial, autologous mesenchymal stem cell infusion for renovascular disease increases blood flow and the glomerular filtration rate while reducing inflammatory biomarkers and blood pressure

Published:2020-04 Issue:4 Volume:97 Page:793-804
ISSN:0085-2538
Container-title:Kidney International
language:en
Short-container-title:Kidney International

Author:

Abumoawad Abdelrhman^ORCID,Saad Ahmed,Ferguson Christopher M.,Eirin Alfonso,Herrmann Sandra M.,Hickson LaTonya J.,Goksu Busra B.,Bendel Emily,Misra Sanjay,Glockner James,Dietz Allan B.,Lerman Lilach O.,Textor Stephen C.

Funder

National Institutes of Health

National Heart, Lung, and Blood Institute

National Institute of Digestive, Diabetic, and Kidney Diseases

Clinical and Translational Science

Publisher

Elsevier BV

Subject

Nephrology

Reference44 articles.

1. Renal-artery stenosis;Safian;N Engl J Med,2001

2. Renovascular hypertension and ischemic nephropathy;Textor;Am J Hypertens,2010